ANI Pharmaceuticals (NASDAQ:ANIP) Shares Pass Above 50-Day Moving Average – Here’s Why

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $80.70 and traded as high as $85.25. ANI Pharmaceuticals shares last traded at $84.11, with a volume of 315,574 shares.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Price Performance

The business has a fifty day moving average of $80.70 and a 200-day moving average of $79.34. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The firm has a market cap of $1.91 billion, a PE ratio of 21.29 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the firm earned $1.70 EPS. The company’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the sale, the director directly owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Stephen P. Carey sold 3,312 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.00, for a total transaction of $264,960.00. Following the completion of the sale, the chief financial officer owned 180,393 shares in the company, valued at $14,431,440. This represents a 1.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 79,016 shares of company stock valued at $6,195,991 in the last three months. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ANIP. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the first quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after acquiring an additional 423 shares during the last quarter. Jane Street Group LLC bought a new position in ANI Pharmaceuticals in the 1st quarter worth about $2,706,000. Finally, Norges Bank purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $625,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.